Christoph Kowalski1, Julia Ferencz2, Peter Albers3, Jan Fichtner4, Thomas Wiegel5, Günter Feick6, Simone Wesselmann7. 1. German Cancer Society, Kuno-Fischer-Straße 8, 14057, Berlin, Germany. kowalski@krebsgesellschaft.de. 2. OnkoZert GmbH, Certification Institute of the German Cancer Society, Gartenstr. 24, 89231, Neu-Ulm, Germany. 3. University Hospital Düsseldorf, Moorenstraße 5, 40225, Düsseldorf, Germany. 4. Johanniter Hospital Oberhausen, Steinbrinkstr. 96, 46145, Oberhausen, Germany. 5. University Hospital Ulm, Albert-Einstein-Allee 23, 89081, Ulm, Germany. 6. Federal Association of German Prostate Cancer Patient Support Groups, Thomas-Mann-Str. 40, 53111, Bonn, Germany. 7. German Cancer Society, Kuno-Fischer-Straße 8, 14057, Berlin, Germany.
Abstract
PURPOSE: In 2008, the German Cancer Society certification program for prostate cancer centers (PCCs) was introduced, fostering multidisciplinary and interprofessional cooperation. Since then, 97 PCCs have been certified. This paper describes the PCC certification program, quality indicators (QI) that are reported during certification, as well as changes over time and correlates of QI fulfillment. METHODS: Observational data from 70,683 primary prostate cancer (PCa) cases treated between 2010 and 2013 in certified PCC sites are analyzed using descriptive and correlation analyses. RESULTS: Fulfillment of the requirements is high with over 80 % of the sites fulfilling the requirements for most of the presented QIs with defined target values. Fulfillment increased slightly over time, with significant improvements in conducting multidisciplinary tumor conferences (increasing proportion of cases presented pre- and post-treatment, increasing participation of specialists), psycho-oncologic care, social service counseling and research participation. Bivariate associations between hospital characteristics and QIs observed were most distinct for time since first certification. CONCLUSIONS: Results suggest that the PCC certification program presented contributes to establishing multidisciplinary teams over time and assures the provision of high-quality PCa care. However, differences in fulfillment of the requirements exist with regard to hospital characteristics beyond the scope of the certification system.
PURPOSE: In 2008, the German Cancer Society certification program for prostate cancer centers (PCCs) was introduced, fostering multidisciplinary and interprofessional cooperation. Since then, 97 PCCs have been certified. This paper describes the PCC certification program, quality indicators (QI) that are reported during certification, as well as changes over time and correlates of QI fulfillment. METHODS: Observational data from 70,683 primary prostate cancer (PCa) cases treated between 2010 and 2013 in certified PCC sites are analyzed using descriptive and correlation analyses. RESULTS: Fulfillment of the requirements is high with over 80 % of the sites fulfilling the requirements for most of the presented QIs with defined target values. Fulfillment increased slightly over time, with significant improvements in conducting multidisciplinary tumor conferences (increasing proportion of cases presented pre- and post-treatment, increasing participation of specialists), psycho-oncologic care, social service counseling and research participation. Bivariate associations between hospital characteristics and QIs observed were most distinct for time since first certification. CONCLUSIONS: Results suggest that the PCC certification program presented contributes to establishing multidisciplinary teams over time and assures the provision of high-quality PCa care. However, differences in fulfillment of the requirements exist with regard to hospital characteristics beyond the scope of the certification system.
Authors: Cora N Sternberg; Michael Krainer; William K Oh; Sergio Bracarda; Joaquim Bellmunt; Haluk Ozen; Alexandre Zlotta; Tomasz M Beer; Stephane Oudard; Michael Rauchenwald; Iwona Skoneczna; Markus M Borner; John M Fitzpatrick Journal: BJU Int Date: 2006-09-06 Impact factor: 5.588
Authors: Quoc-Dien Trinh; Anders Bjartell; Stephen J Freedland; Brent K Hollenbeck; Jim C Hu; Shahrokh F Shariat; Maxine Sun; Andrew J Vickers Journal: Eur Urol Date: 2013-04-19 Impact factor: 20.096
Authors: Riccardo Valdagni; Peter Albers; Chris Bangma; Lawrence Drudge-Coates; Tiziana Magnani; Clare Moynihan; Chris Parker; Kathy Redmond; Cora N Sternberg; Louis Denis; Alberto Costa Journal: Eur J Cancer Date: 2010-12-01 Impact factor: 9.162
Authors: Leonard G Gomella; Jianqing Lin; Jean Hoffman-Censits; Patricia Dugan; Fran Guiles; Costas D Lallas; Jaspreet Singh; Peter McCue; Timothy Showalter; Richard K Valicenti; Adam Dicker; Edouard J Trabulsi Journal: J Oncol Pract Date: 2010-11 Impact factor: 3.840
Authors: Clara Breidenbach; Rebecca Roth; Lena Ansmann; Simone Wesselmann; Sebastian Dieng; Ernst-Günther Carl; Günter Feick; Alisa Oesterle; Peter Bach; Burkhard Beyer; Rainer Borowitz; Jörg Erdmann; Frank Kunath; Simba-Joshua Oostdam; Igor Tsaur; Friedemann Zengerling; Christoph Kowalski Journal: Cancer Med Date: 2020-03-31 Impact factor: 4.452
Authors: Rebecca Roth; Sebastian Dieng; Alisa Oesterle; Günter Feick; Günther Carl; Andreas Hinkel; Thomas Steiner; Björn Theodor Kaftan; Frank Kunath; Boris Hadaschik; Simba-Joshua Oostdam; Rein Jüri Palisaar; Mateusz Koralewski; Burkhard Beyer; Björn Haben; Igor Tsaur; Simone Wesselmann; Christoph Kowalski Journal: World J Urol Date: 2020-02-10 Impact factor: 4.226